Automated methods of detecting cell free DNA

Patent metadata

Field	Value
Publication number	US-12344901-B2
Application number	US-202217883414-A
Country	US
Kind code	B2
Filing date	Aug 8, 2022
Priority date	Mar 22, 2016
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.

First claim

The invention claimed is:

1. An automated method of detecting a DNA fragment, comprising:
(i) receiving, via an application module configured to receive commands from at least one of a user computing device or a script server, a workflow process corresponding to a result to be obtained based on operations on a sample selected from whole blood, plasma, or serum from a subject with a history of cancer;
(ii) obtaining, via an automation system configured to interface with laboratory equipment, based on the workflow process, a container with the sample from an origin location;
(iii) performing, by the automated system,
(a) extracting cell free DNA (cfDNA) from the sample;
(b) enriching, from the extracted cfDNA, a DNA fraction of fragments comprising one or more of a plurality of tumor-specific somatic mutations that are specific to the subject and that were determined prior to obtaining the sample by sequencing genomic DNA from a solid tumor sample previously obtained from the subject and genomic DNA from a non-tumor sample previously obtained from the subject;
(c) sequencing the enriched fraction of fragments; and
(d) detecting a presence or absence of a DNA fragment comprising any one of the plurality of tumor-specific somatic mutations in the enriched DNA fraction of fragments; and

(iv) generating a report comprising the result of the detection of the presence or absence of the DNA fragment.

2. The method of claim 1 , wherein the cfDNA is extracted from the sample using a liquid handling apparatus configured for extraction of components of samples.

3. The method of claim 1 , further comprising providing, by the application module, the report to a user device.

4. The method of claim 1 , wherein the result is presence or absence of a molecule in the sample.

5. The method of claim 1 , wherein the automation system is configured to interface with the laboratory equipment using one or more robotics units.

6. The method of claim 1 , wherein the enriching comprises hybrid capture-based enrichment, PCR-target enrichment, or on-sequencer enrichment.

7. The method of claim 1 , wherein the method comprises a detection sensitivity of 20 to 50 ctDNA fragments comprising one or more of the plurality of somatic mutations in fluid sample per a total background of 500,000 cfDNA fragments.

8. The method of claim 1 , wherein hybrid capture-based enrichment is used to enrich the DNA fraction of fragments comprising one or more of the plurality of tumor-specific somatic mutations.

9. The method of claim 8 , wherein hybrid capture-based enrichment comprises:
(i) contacting the extracted cfDNA with a plurality of oligonucleotides that each comprise a nucleic acid sequence that is capable of hybridizing to one of the plurality of tumor-specific somatic mutations; and
(ii) selectively enriching cfDNA fragments that hybridize to the plurality of oligonucleotides.

10. The method of claim 9 , wherein the plurality of oligonucleotides is capable of detecting at least 10 different tumor-specific somatic mutations.

11. The method of claim 1 , wherein sequencing comprises whole genome sequencing.

12. The method of claim 1 , wherein sequencing comprises targeted sequencing.

13. The method of claim 1 , further comprising determining a fraction of the cfDNA fragments that are circulating tumor DNA (ctDNA) fragments.

14. The method of claim 1 , wherein the mutations in the plurality of tumor-specific somatic mutations comprise one or more mutations selected from SNPs, insertions, deletions, and translocations.

15. The method of claim 1 , further comprising repeating the method on a second sample obtained from the subject at a later date.

Assignees

• Myriad Womens Health Inc

Inventors

• Maguire Jared Robert
• Chu Clement S
• Haque Imran Saeedul
• Evans Eric Andrew
• Welker Noah

Classifications

• G01N35/0099

  comprising robots or similar manipulators (robots per se B25J) · CPC title

• C12Q1/6818 Primary

  involving interaction of two or more labels, e.g. resonant energy transfer · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6874

  involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title